The case for routine use of adjuvant therapy in pancreatic cancer

✍ Scribed by Eugene P. Kennedy; Charles J. Yeo

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 110 KB
• Volume: 95
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.20719

✦ Synopsis

Abstract

Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long‐term survival. Even with optimal surgical management, 5‐year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy. J. Surg. Oncol. 2007;95:597–603. © 2007 Wiley‐Liss, Inc.